IDORSIA N news, videos and press releases
For more news please use our advanced search feature.
IDORSIA N - More news...
IDORSIA N - More news...
- Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
- US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
- Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
- New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
- Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
- New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023
- Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic Stress Disorder (PTSD)
- Idorsia Files Petition with the Drug Enforcement Administration (DEA) Urging Them to De-Schedule Dual Orexin Receptor Antagonist Class of Insomnia Medications
- On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder
- Simcere and Idorsia enter into a licensing agreement for daridorexant in China
- Idorsia Announces its Insomnia Medication, QUVIVIQ (daridorexant), is now Covered by TRICARE
- Idorsia announces financial results for the first half 2022 – reaching commercial stage
- Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
- Idorsia's new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
- PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan
- World Premiere: The Quest for Sleep, a Film Narrated by Octavia Spencer, Explores People's Struggles with Insomnia and the Fascinating Science Behind How and Why We Sleep
- Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management
- Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada
- Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep
- Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA
- Idorsia Convenes The Alliance for Sleep, a Force for Innovation and Change in the Insomnia Space
- Invitation to Idorsia's half year financial results 2021 webcast and conference call
- Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
- Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA
- Veeva Commercial Cloud Selected by Idorsia to Accelerate Digital Engagement Globally
- Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
- Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States
- Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
- Idorsia announces financial results for the first half 2020
